United Kingdom. 22 June 2020. A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash Monga, Mehdi Javanbakht, Ph.D.)
You can read details of the report here
This is great news for women suffering with this debilitating condition, for the clinicians who treat these women and for Seroba’s portfolio company, Atlantic Therapeutics, the makers of INNOVO®.
This week is World Continence Week 2020 ( 17 – 23 June). During the week The Urology Foundation highlights the impact urinary incontinence can have on lives and encourages those living with it to seek help so they no longer have to suffer in silence.
About Atlantic Therapeutics
Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. INNOVO® from Atlantic Therapeutics is an FDA-cleared, externally applied, patented CE device that delivers a safe, clinically effective and comfortable therapy to treat reversible clinical conditions associated with pelvic floor weakness in the comfort of the user’s own home. Learn more at: www.myinnovo.com.